Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B2278 in chronic heart failure
NCT07265349Phase 2Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of B2278 in chronic heart failure (CHF), ischemic cardiomyopathy (ICM), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
B2278
03
Conditions
chronic heart failure (CHF)ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT07265349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265349.